Denemek ALTIN - Özgür
Tata Steel capacity target faces analysts’ scepticism
Mint Mumbai
|October 06, 2025
Beyond Kalinganagar and NINL, company has no announced plans to meet 40mtpa target
Once projects are done, Tata Steel can reach 31-32 mtpa capacity, far from target.
(AFP)
Tata Steel Ltd's ambitious plan to boost steelmaking is facing scepticism, as execution roadmaps beyond its immediate pipeline remain unclear.
At the close of fiscal year 2025 (FY25), Tata Steel's local capacity stood at just 26.6 million tonnes per annum (mtpa), far from the target of 40 mtpa by FY30 that chairman N. Chandrasekaran set in July 2024.
Apart from the two expansion projects already announced for Kalinganagar and subsidiary Neelachal Ispat Nigam Ltd (NNL), the company's road to 40 mtpa remains unclear, analysts said.
The main goal is to ramp up Kalinga-nagar to full capacity utilization of 8 mtpa by the end of 2025. This is a critical step, as the expansion helps Tata Steel serve demand in the near term. The other is to scale up NINL. While its expansion is critical-it will help Tata Steel sell long steel used in construction, infrastructure and appliance industries-the clearances to expand its capacity from 1 mtpa to 5 mtpa are still awaited.
Once both expansion projects are completed, Tata Steel will achieve a capacity of 31-32 mtpa, still far from its target.
Tata Steel did not respond to queries seeking comments.
Bu hikaye Mint Mumbai dergisinin October 06, 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Mint Mumbai'den DAHA FAZLA HİKAYE
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

